Orchestra BioMed Holdings, Inc.
For the period ended Dec 31, 2025. Filed Mar 12, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 12, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Signatures
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| | ORCHESTRA BIOMED HOLDINGS, INC. | ||
|---|---|---|---|
| | | ||
| Date: March 12, 2026 | By: | /s/ David P. Hochman | |
| | | Name: | David P. Hochman |
| | | Title: | Chief Executive Officer |
| | | | (Principal Executive Officer) |
POWER OF ATTORNEY
KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints David P. Hochman and Andrew L. Taylor, and each of them, as his or her attorneys-in-fact, each with the power of substitution, for him or her in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that each of said attorneys-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Name | | Title | | Date |
|---|---|---|---|---|
| /s/ David P. Hochman | Chief Executive Officer, Chairperson and Director | March 12, 2026 | ||
| David P. Hochman | (Principal Executive Officer) | |||
| /s/ Andrew L. Taylor | Chief Financial Officer | March 12, 2026 | ||
| Andrew L. Taylor | (Principal Financial Officer) | |||
| /s/ Joshua Aiello | Corporate Controller | March 12, 2026 | ||
| Joshua Aiello | (Principal Accounting Officer) | |||
| /s/ Jason Aryeh | Director | March 12, 2026 | ||
| Jason Aryeh | ||||
| | | | | |
| /s/ Chris Cleary | | Director | | March 12, 2026 |
| Chris Cleary | | | | |
| /s/ Pamela A. Connealy | Director | March 12, 2026 | ||
| Pamela A. Connealy | ||||
| /s/ Eric S. Fain, M.D. | Director | March 12, 2026 | ||
| Eric S. Fain, M.D. | ||||
| | | | | |
| /s/ John Mack | | Director | | March 12, 2026 |
| John Mack | | | | |
| /s/ David Pacitti | Director | March 12, 2026 | ||
| David Pacitti | ||||
| | | | | |
| /s/ Darren R. Sherman | President, Chief Operating Officer and Director | March 12, 2026 | ||
| Darren R. Sherman | | | | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.